ATM c.4310G>A ;(p.R1437K)

Variant ID: 11-108160402-G-A

NM_000051.3(ATM):c.4310G>A;(p.R1437K)

This variant was identified in 6 publications

View GRCh38 version.




Publications:


Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China.

Bmc Medical Genomics
Liu, Jing J; Li, Zirong Z; Lu, Ting T; Pan, Junping J; Li, Li L; Song, Yanwen Y; Hu, Dan D; Zhuo, Yanhong Y; Chen, Ying Y; Xu, Qin Q
Publication Date: 2022-11-04

Variant appearance in text: ATM: 4310G>A; Arg1437Lys
PubMed Link: 36333792
Variant Present in the following documents:
  • 12920_2022_1376_MOESM1_ESM.xlsx, sheet 1
View BVdb publication page



Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.

Npj Precision Oncology
Schaufler, Diana D; Ast, David F DF; Tumbrink, Hannah L HL; Abedpour, Nima N; Maas, Lukas L; Schwäbe, Ayla E AE; Spille, Inga I; Lennartz, Stefanie S; Fassunke, Jana J; Aldea, Mihaela M; Besse, Benjamin B; Planchard, David D; Nogova, Lucia L; Michels, Sebastian S; Kobe, Carsten C; Persigehl, Thorsten T; Westphal, Theresa T; Koleczko, Sophia S; Fischer, Rieke R; Weber, Jan-Phillip JP; Altmüller, Janine J; Thomas, Roman K RK; Merkelbach-Bruse, Sabine S; Gautschi, Oliver O; Mezquita, Laura L; Büttner, Reinhard R; Wolf, Jürgen J; Peifer, Martin M; Brägelmann, Johannes J; Scheffler, Matthias M; Sos, Martin L ML
Publication Date: 2021-12-17

Variant appearance in text: ATM: R1437K
PubMed Link: 34921211
Variant Present in the following documents:
  • Main text
  • 41698_2021_Article_241.pdf
View BVdb publication page



Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.

Npj Precision Oncology
Schaufler, Diana D; Ast, David F DF; Tumbrink, Hannah L HL; Abedpour, Nima N; Maas, Lukas L; Schwäbe, Ayla E AE; Spille, Inga I; Lennartz, Stefanie S; Fassunke, Jana J; Aldea, Mihaela M; Besse, Benjamin B; Planchard, David D; Nogova, Lucia L; Michels, Sebastian S; Kobe, Carsten C; Persigehl, Thorsten T; Westphal, Theresa T; Koleczko, Sophia S; Fischer, Rieke R; Weber, Jan-Phillip JP; Altmüller, Janine J; Thomas, Roman K RK; Merkelbach-Bruse, Sabine S; Gautschi, Oliver O; Mezquita, Laura L; Büttner, Reinhard R; Wolf, Jürgen J; Peifer, Martin M; Brägelmann, Johannes J; Scheffler, Matthias M; Sos, Martin L ML
Publication Date: 2021-12-17

Variant appearance in text: ATM: R1437K
PubMed Link: 34921211
Variant Present in the following documents:
  • Main text
  • 41698_2021_Article_241.pdf
View BVdb publication page



mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis.

Cell Reports
Triki, Mouna M; Rinaldi, Gianmarco G; Planque, Melanie M; Broekaert, Dorien D; Winkelkotte, Alina M AM; Maier, Carina R CR; Janaki Raman, Sudha S; Vandekeere, Anke A; Van Elsen, Joke J; Orth, Martin F MF; Grünewald, Thomas G P TGP; Schulze, Almut A; Fendt, Sarah-Maria SM
Publication Date: 2020-06-23

Variant appearance in text: ATM: R1437K
PubMed Link: 32579932
Variant Present in the following documents:
  • mmc5.xlsx, sheet 3
View BVdb publication page



LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype.

Frontiers In Oncology
Cao, Canhui C; Lin, Shitong S; Zhi, Wenhua W; Lazare, Cordelle C; Meng, Yifan Y; Wu, Ping P; Gao, Peipei P; Wei, Juncheng J; Wu, Peng P
Publication Date: 2020

Variant appearance in text: ATM: R1437K
PubMed Link: 32211324
Variant Present in the following documents:
  • Table_1.xls, sheet 6
View BVdb publication page



Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.

Communications Biology
Dong, Xiaobao X; Huang, Dandan D; Yi, Xianfu X; Zhang, Shijie S; Wang, Zhao Z; Yan, Bin B; Chung Sham, Pak P; Chen, Kexin K; Jun Li, Mulin M
Publication Date: 2020-01-07

Variant appearance in text: ATM: 4310G>A; R1437K
PubMed Link: 31925297
Variant Present in the following documents:
  • 42003_2019_736_MOESM3_ESM.xlsx, sheet 1
View BVdb publication page



Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors.

Elife
Yamamoto, Kenta K; Wang, Jiguang J; Sprinzen, Lisa L; Xu, Jun J; Haddock, Christopher J CJ; Li, Chen C; Lee, Brian J BJ; Loredan, Denis G DG; Jiang, Wenxia W; Vindigni, Alessandro A; Wang, Dong D; Rabadan, Raul R; Zha, Shan S
Publication Date: 2016-06-15

Variant appearance in text: ATM: R1437K
PubMed Link: 27304073
Variant Present in the following documents:
  • elife-14709-supp1.xlsx, sheet 2
View BVdb publication page